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Abstract
Introduction
The global epidemic of type II diabetes has proven to exist as one of the greatest 
clinically perplexing diseases of the twenty first century. Considerable evidence 
suggests type II diabetes is a multifactorial disease with robust genetically related 
components. According to Sanghera and Blackett (2012), recent genome-wide 
association studies have effectively recognized and replicated between 60-75 
susceptibility loci correlated with type II diabetes and interrelated metabolic traits. 
Genome wide association studies function as an introduction to forthcoming genetic 
and functional research, considering the specific mechanisms by which type II 
diabetes linked genes sway disease remains uncertain. Further lending to problematic 
implication of current genetic discoveries into clinical environments. Conversely, 
evidence has progressively exposed novel underlying type II diabetes molecular 
pathways, etiology, gene-environment interactions, epigenetic modifications, and 
gene function. Although large scale, time-consuming and painstaking genome wide 
association studies have successfully identified common risk alleles correlated with 
type II diabetes with sufficient statistical power, these studies should further consider 
how the information gained can ultimately be converted into early intervention and 
prediction of type II diabetes (Kato 2013). 
Research Question
Literature Review
Applicability to Clinical 
Practice
Discussion
• Wu et al. (2014) conducted research that resulted in genetic loci related to 
hyperglycemia progression to type II diabetes. 
• Franceschini et al. (2013) conducted research that resulted in genetic loci in 
proximity to genes which affect pancreatic beta cell development. 
• Kato (2013) conducted research resulting in the discovery of type II diabetes genes 
located in intergenetic regions. 
• Wu et al. (2014) conducted research resulting in type II diabetes concordance rates 
among twins and first-degree relatives. 
• Hanson et al. (2013) conducted a study resulting in inherited type II diabetes genes 
in Native American people. 
• Su, Yu and Hu (2014) conducted research resulting in the utility of a concept 
known as pharmacogenomics. 
• Pal and McCarthy (2013) conducted research resulting in clinical application of 
type II diabetes genetic data.  
As the seventh leading cause of death in the United States, diabetes affects 29.1 
million people. In May, 2015 the U.S. CDC reported, the estimated total financial 
burden for diabetes in the United States at greater than $245 billion ($69 billion 
attributed to disability, lost days at work and premature death). The purpose of this 
study was to investigate genetic variances in parallel with type II diabetes. Through a 
five year prior search of Cochrane, Medline and Pubmed this review of the literature 
examined studies regarding type II diabetes related genetic variances specific to non-
ethnic and ethnic populations of otherwise healthy adults aged 18-65 years old. 
Methods encompassed extracting DNA from nuclear pellets. Further genotyping was 
conducted using SNPlex or Assays on Demand. A p value of less than 0.05 was 
considered statistically significant. Literature reviews utilized centre-stratified 
analyses, combining evidence from each centre using fixed-effect meta-analyses. The 
authors then assessed research subjects against controls utilizing measured 
genotype and additive genetic models adjusted for age and gender. Significance 
thresholds were then adjusted where a p value of < 0.05 was considered statistically 
significant. Franceschini et al. (2013), Wu et al. (2014) Hanson et al. (2013), Kato 
(2013), Yagootak and Frayling (2013), Sun, Yu and Hu (2014) and Pal and McCarthy 
(2013) stated over 60 genetic loci have been identified to date in candidate gene and 
genome-wide association studies regarding type II diabetes. Of the genetic loci 
discovered, Wu et al. (2014) and Yagatook and Frayling (2013) determined variants at 
TCF7L2 resemble the most robust correlation with type II diabetes. Wu et al. (2014) 
found a 96% concordance rate among monozygotic twins with type II diabetes, as 
well as a 40% incidence rate of developing type II diabetes among those who have 
first-degree relatives with the disease. However, Kato (2013) suggests previous studies 
only account for 5-10% of heritability associated with type II diabetes. Sun, Yu and 
Hu (2014) reported the concept of pharmacogenomics (drug molecular mechanisms 
related to gene variants and drug efficacy) may eventually drive clinical decision 
making regarding type II diabetes drug selection, dose titration and adverse side 
effect avoidance. Based on the results of the studies in this review, accurate genetic 
data reveals potential to evolve clinically into a valuable instrument, thereby 
facilitating optimized therapeutics and deferring or suspending the onset of type II 
diabetes.
What genetic factors are responsible for the increasing incidence of type II diabetes 
among adults?
• According to Franceschini et al. (2013) and Wu et al. (2014) evidence to date 
suggests there exists a utility regarding genetic evaluation of glycaemic 
deterioration from hyperglycemia to type II diabetes.
• Franceschini et al. (2013), Wu et al. (2014) Hanson et al. (2013), Kato (2013), 
Yagootak and Frayling (2013), Sun, Yu and Hu (2014) and Pal and McCarthy (2013) 
all concur that over 60 genetic loci have been identified in candidate gene and 
genome-wide association studies regarding type II diabetes.
• Franceschini et al. (2013) propose several of the 60 identified loci are located in or 
near-by genes affecting pancreatic beta cell development and function, related to 
insulin secretion.
• Kato (2013) suggests KLF14 is more commonly is found in Europeans with type II 
diabetes, however not in East and South Asians. (See Figure 1.)
• Kato (2013) suggests some gene variant loci are not in fact neighboring observable 
candidate genes, however are often located in areas known as intergenetic regions. 
(See Figure 2.)
• Wu et al. (2014) proposes a 96% concordance rate among monozygotic twins with 
type II diabetes, as well as a 40% incidence rate of developing type II diabetes 
among those who have first-degree relatives with the disease.
• Hanson et al. (2013) suggest there exists a strong parent-of-origin effect within 
recently identified gene single nucleotide polymorphisms which confirm 
susceptibility to type II diabetes among Native American people.
• Kato (2013) suggests previous studies only account for 5-10% of heritability 
associated with type II diabetes, through factors such as insufficient surveys of rare 
variants, inaccuracy of current heritability estimates and epigenetics.
• Wu et al. (2014) and Yagatook and Frayling (2013) agree, of the genetic loci 
discovered, variants at TCF7L2 resemble the most robust correlation with type II 
diabetes.
• Su, Yu and Hu (2014) propose the aim of pharmacogenomics is to explore molecular 
mechanisms of type II diabetes therapeutics as they relate to specific gene variants.
• Pal and McCarthy (2013) concur with Su Yu and Hu (2014), stating if major 
discoveries into type II diabetes pathogenesis are discovered, these unique 
mechanisms potentially give rise to enriched treatment outcomes.
• Wu et al. (2014) suggests type II diabetes susceptibility loci exhibit a polygenic 
phenomenon where heritability is subsequently determined by a large number of 
genes, each having a nominal mass effect.
• Hanson et al. (2013) hypothesize; the population variances in genetic risk scores 
between Native Americans, East Asians and Africans could represent alterations 
presentative of genetic drift or natural selection.
• Yaghootak and Frayling (2013) suggest evidence from prior studies  reveals a direct 
yet sometimes paradoxical relationship between genetic variants and metabolic 
traits known to be in close relationship to type II diabetes risk.
• With more than 70 genetic loci identified that correlate to type II diabetes 
susceptibility, further investigation and narrowing of these novel findings is 
advised by those within the research community. 
• Although several genetic variants have been identified and further studied for 
prediction value of type II diabetes, these genetic variants only marginally 
improved prediction beyond noninvasive characteristics in previous studies. 
• Specific genetic loci such as KNCJ11 and PPARG2 serve as therapeutic targets for 
specific antihyperglycemic agents such as sulfonylurea and thiazolidinedione 
classes of medications. 
• Research suggests variations of multiple gene loci are correlated with clinical 
variation in oral antidiabetic drug tolerance, effect, glycemic response and 
tolerance by individual patients. 
Statement of the Problem
According to the Centers for Disease Control, diabetes is the 7th leading cause of 
death in the United States. Enhanced predictive, preventative and therapeutic 
methodologies are warranted to defray morbidity and mortality from this debilitating 
and deadly disease. 
References
Franceschini N(1), H. K. (2013). Epidemiology and genetic      determinants of 
progressive deterioration of glycaemia. Diabetologia, 56(10), 1-5.
Frayling, H. Y. (2013). Recent progress in the use of genetics to understand links 
between type 2 diabetes and related metabolic traits. Genome Biology, 1-5.
Hanson RL(1), G. T. (2013). Strong parent-of-origin effects in the association of 
KCNQ1 variants with type 2. Diabetes, 62(8), 2-6.
Kato, N. (2013). Insights into the genetic basis of type 2 diabetes . Journal of 
Diabetes Investigation , 233-242.
McCarthy MI(1), Z. E. (2009). Genome-wide association studies in type 2 diabetes. 
Current Diabetes Reports, 9(2).
Sun X(1), Y. W. (2014). Genetics of type 2 diabetes: insights into the pathogenesis 
and its clinical. Biomedical Research Institute, 1-4.
Wu Yaling, Y. D. (2014). Risk Factors Contributing to Type 2 Diabetes and Recent 
Advances in the Treatment and Prevention. International Journal of Medical 
Sciences, 1185-1196.
Pal A(1), M. M. (2013). The genetics of type 2 diabetes and its clinical relevance. 
Clinical Genetics, 83(4).
Figure 1. Risk Allele Frequency.
Risk allele frequencies and effect sizes of known susceptibility 
loci for type II diabetes , which have shown significant (P ≤ 5 ×
10−8) association. Identified in populations of European 
descent, some were exclusively found or first reported in 
non‐European populations (Kato 2013).
Figure 1. Risk Allele Frequency.
Figure 2. Intertrait Overlap
Figure 2. Intertrait Overlap
Intertrait difference (or overlapping) for 41 diabetes‐related trait 
associated loci that have been reported in meta‐analyses of 
genome‐wide association studies. The traits include fasting plasma 
glucose (FPG), insulin and its related‐traits (homeostasis model 
assessment of β‐cell function (HOMA‐B) and HOMA of insulin 
resistance), and glycated hemoglobin (HbA1c). Here, an associated locus 
is assumed to overlap between the traits when P ≤ 5 × 10−8 was 
concordantly attained. Underlined are the loci that have shown 
significant (P ≤ 5 × 10−8) association with type 2 diabetes; at three loci 
with asterisks – ANK1,CDKAL1 and GRB14 – variants associated with 
individual traits are not in linkage disequilibrium (r2 < 0.3) (Kato 2013).
